Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Frankfurt - Delayed Quote EUR

Royalty Pharma plc (RPD.F)

Compare
30.96
+0.17
+(0.55%)
As of 8:44:38 AM GMT+1. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
2,263,576
2,263,576
2,354,554
2,237,215
2,289,463
Operating Expense
971,132
971,132
862,404
1,314,323
858,748
Operating Income
1,292,444
1,292,444
1,492,150
922,892
1,430,715
Net Non Operating Interest Income Expense
-178,169
-178,169
-114,896
-109,626
-112,607
Other Income Expense
216,538
216,538
322,834
-583,202
-76,907
Pretax Income
1,330,813
1,330,813
1,700,088
230,064
1,241,201
Net Income Common Stockholders
858,983
858,983
1,134,834
42,832
619,728
Average Dilution Earnings
276,893
276,893
392,726
--
--
Diluted NI Available to Com Stockholders
1,135,876
1,135,876
1,527,560
42,832
619,728
Basic EPS
2.56
1.93
2.54
0.10
1.49
Diluted EPS
2.54
1.45
2.53
0.10
1.49
Basic Average Shares
448,293.25
445,985
447,601
437,963
414,794
Diluted Average Shares
596,124.50
594,000
602,900
437,972
414,802
Total Operating Income as Reported
1,292,444
1,292,444
1,492,150
307,065
1,430,715
Total Expenses
971,132
971,132
862,404
1,314,323
858,748
Net Income from Continuing & Discontinued Operation
858,983
858,983
1,134,834
42,832
619,728
Normalized Income
670,528
670,528
819,145
602,306
671,467
Interest Income
47,343
47,343
72,291
78,335
53,535
Interest Expense
225,512
225,512
187,187
187,961
166,142
Net Interest Income
-178,169
-178,169
-114,896
-109,626
-112,607
EBIT
1,556,325
1,556,325
1,887,275
418,025
1,407,343
EBITDA
1,556,325
1,556,325
1,887,275
423,695
1,430,339
Reconciled Depreciation
--
--
--
5,670
22,996
Net Income from Continuing Operation Net Minority Interest
858,983
858,983
1,134,834
42,832
619,728
Total Unusual Items Excluding Goodwill
188,455
188,455
315,689
-559,474
-51,739
Total Unusual Items
188,455
188,455
315,689
-559,474
-51,739
Normalized EBITDA
1,367,870
1,367,870
1,571,586
983,169
1,482,078
12/31/2021 - 10/13/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

HQ1.MU Oruka Therapeutics Inc. R
9.60
0.00%
 
5KW.F SkinBioTherapeutics plc
0.2160
-2.70%
 
5CV.MU CureVac NV
2.8900
+0.35%
 
AM6.F Amicus Therapeutics, Inc.
8.40
-1.18%
 
ICY.SG Incyte Corp
64.34
+0.06%
 
600161.SS TIANTAN BIO
19.88
+0.05%
 
GON.DU Geron Corp
1.5600
+0.13%
 
1S9.SG Seres Therapeutics Inc
0.6902
+1.77%
 
ISI.F Ionis Pharmaceuticals, Inc.
31.00
-0.06%
 
2H51.DU Ocugen Inc
0.5390
+3.95%